Related Experiment Videos

Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder?

Martin C Michel1, Jean J M C H de la Rosette, Maria Piro

  • 1Department of Pharmacology and Pharmacotherapy, University of Amsterdam, The Netherlands. m.c.michel@amc.uva.nl

The Journal of Urology
|July 13, 2004
PubMed
Abstract

Insights

Tolterodine effectively treats overactive bladder (OAB) symptoms. However, patients with severe stress incontinence (SI) experience less improvement in frequency and incontinence compared to those with mild or no SI.

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Overactive bladder (OAB) is commonly treated with muscarinic antagonists like tolterodine.
  • Concomitant stress incontinence (SI) can affect treatment outcomes in OAB patients.

Purpose of the Study:

  • To evaluate the impact of concurrent stress incontinence (SI) on the efficacy of tolterodine in patients with overactive bladder (OAB).

Main Methods:

  • An open-label, observational study analyzed data from 2,250 OAB patients over 12 weeks.
  • Tolterodine treatment (2 mg twice daily) effects on frequency, urgency, and incontinence were assessed.
  • Multiple regression analysis adjusted for demographic and baseline symptom factors.

Main Results:

  • Tolterodine significantly reduced OAB symptoms in the overall patient group.
  • Patients with mild (I) or moderate (II) degree SI showed minimal impact on tolterodine efficacy.
  • Severe (III) degree SI was associated with statistically significant smaller reductions in urinary frequency and incontinence episodes.

Conclusions:

  • Concomitant mild (I) or moderate (II) degree stress incontinence has a negligible effect on tolterodine's efficacy for overactive bladder.
  • Only patients with severe (III) degree stress incontinence exhibit significantly reduced improvement with tolterodine treatment.

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...